Brief: Hutchmed (China) Says NDA For Fanregratinib Accepted With Priority Review In China
29/12/2025 10:29
Dec 29 (Reuters) - HUTCHMED (China) Ltd 0013.HK: NDA FOR FANREGRATINIB ACCEPTED WITH PRIORITY REVIEW IN CHINA Further company coverage: 0013.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation